CEL-SCI Reports 146 Patients Enrolled In Its Phase 3 Immunotherapy Head And Neck Cancer Trial

Published: Feb 27, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT:CVM) today reported accelerating progress in patient enrollment in the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Approximately 146 patients have been enrolled in the Phase III study to date.

Help employers find you! Check out all the jobs and post your resume.

Back to news